CLEVELAND, Nov. 12 /PRNewswire/ -- Intelect Medical, Inc., an early
stage company developing an implantable neuromodulation system for stroke
and traumatic brain injury recovery, announced it has closed a licensing
and financing deal, led by existing investor Boston Scientific Corporation
(NYSE: BSX). Existing investor, Greatbatch, Inc. (NYSE: GB), also
participated in the equity portion of the round that will provide between
$11 million and $13.5 million plus the potential for future payments. The
company plans to use the proceeds to continue its investigational work on
traumatic brain injury (TBI) recovery therapy, in an expanded clinical
feasibility study in Europe, and for a U.S. trial for its stroke recovery
therapy, both using deep brain stimulation (DBS).

As part of the arrangement, Boston Scientific receives a co-exclusive
license to Intelect's Dimension(R) Visual Programming Software for certain
fields of use within DBS. The Dimension(R) software, currently under
development, will provide clinicians with graphical information about
changes in the stimulation field created around electrodes in the brain as
electrical parameters are adjusted. Intelect's software is based on the
work of Cameron McIntyre, Ph.D. and his colleagues at the Cleveland
Clinic's Lerner Research Institute Department of Biomedical Engineering.

"We are pleased to broaden our partnership with Intelect Medical," said
Michael Onuscheck, President of Boston Scientific Neuromodulation. "This
relationship will improve our foot print into the DBS space and enable
Intelect Medical to pursue their landmark research."

Vince Owens, President and Chief Executive Officer of Intelect Medical,
said "This funding from Boston Scientific and Greatbatch will support our
on-going R&D efforts related to our Enspire(TM) DBS Therapy system and
additional clinical studies of our DBS therapies for stroke and TBI
recovery in the U.S. and Europe."

"Greatbatch is committed to supporting the large and growing
Neuromodulation device market," said Thomas J. Hook President and Chief
Executive Officer of Greatbatch, Inc. "We are pleased to provide funding
for Intelect to further develop its innovative DBS therapies and products."

Intelect Medical was incorporated in 2005, as a spin out of both the
Cleveland Clinic and Cornell to develop new DBS therapies for recovery from
stroke and TBI. Intelect's stroke recovery therapy is based on the work of
Andre Machado, M.D. and his colleagues at Cleveland Clinic's Center for
Neurological Restoration. The company's traumatic brain injury technology,
based on the work of Nicholas Schiff, M.D., was licensed through the
Cornell Center for Technology Enterprise and Commercialization (CCTEC), the
technology transfer arm of the Weill Cornell Medical College. The Cleveland
Clinic Foundation and Cornell Research Foundation, Inc. are shareholders in
Intelect Medical.

About Stroke and Traumatic Brain Injury (TBI)

Both stroke and TBI are leading causes of serious, long-term disability
worldwide. According to the National Institute for Neurological Disorders
and Stroke, these two disabilities combined have an annual incidence of 2.2
million, while creating in excess of $115 billion in direct healthcare
costs annually. Four million people in the United States are survivors of
stroke and more than 5 million suffer from TBI disabilities.

About Intelect Medical

Intelect Medical, Inc., headquartered in Cleveland, OH, is an early
stage medical device company focused on providing neuromodulation solutions
to patients suffering with disabilities from stroke and traumatic brain
injury. For more information, visit http://www.intelectmedical.com.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer
of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
http://www.bostonscientific.com/.

About Greatbatch, Inc.

Greatbatch, Inc. (NYSE: GB) is a leading company that designs and
manufactures high quality, innovative products and systems for customers in
the cardiac rhythm management, neuromodulation, vascular and orthopedic
markets. Additionally, Electrochem, a subsidiary of Greatbatch, is a world
leader in the design and manufacture of technology solutions for some of
the world's most demanding and extreme applications. Additional information
about the Company is available at http://www.greatbatch.com.

About Cleveland Clinic

Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit
multispecialty academic medical center that integrates clinical and
hospital care with research and education. Cleveland Clinic was founded in
1921 by four renowned physicians with a vision of providing outstanding
patient care based upon the principles of cooperation, compassion and
innovation. U.S. News & World Report consistently names Cleveland Clinic as
one of the nation's best hospitals in its annual "America's Best Hospitals"
survey. Approximately 1,800 full-time salaried physicians and researchers
at Cleveland Clinic and Cleveland Clinic Florida represent more than 100
medical specialties and subspecialties. In 2007, there were 3.5 million
outpatient visits to Cleveland Clinic and 50,455 hospital admissions.
Patients came for treatment from every state and from more than 80
countries. Cleveland Clinic's Web site address is
http://www.clevelandclinic.org/.

Disclosure: The Cleveland Clinic Foundation is a shareholder in
Intelect Medical. In addition, CCF employees have the right to receive
stock from Intelect Medical, and serve as paid consultants to Intelect
Medical. One CCF official serves on its Board of Directors.

About Weill Cornell Medical College

Weill Cornell Medical College -- located in New York City -- is
committed to excellence in research, teaching, patient care and the
advancement of the art and science of medicine. Weill Cornell, which is a
principal academic affiliate of New York-Presbyterian Hospital, is the
birthplace of many medical advances -- from the development of the Pap test
for cervical cancer to the synthesis of penicillin, the first successful
embryo-biopsy pregnancy and birth in the U.S., and most recently, the
world's first clinical trial for gene therapy for Parkinson's disease.
Weill Cornell's Physician Organization includes 650 clinical faculty, who
provide the highest quality of care to their patients. For more
information, visit http://www.med.cornell.edu.

(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...

(Date:12/8/2016)... , ... December 08, 2016 , ... The Compretta Insurance ... and residential clients in and around the Hancock County area, is announcing the launch ... County Food Pantry. , The Hancock County Food Pantry has worked for more than ...

(Date:12/8/2016)... , December 8, 2016 According ... Diabetes Injection Pens Market is expected to be worth ... US$4.9 bn in 2015. Between the forecast years of 2016 ... a CAGR of 7.9%. The leading players operating in the ... Lilly and Company, AstraZaneca plc., Biocon Ltd., and Sanofi S.A. ...